Barzolvolimab clinical trials
Also written CDX-0159.
ClinicalTrials.gov finds 10 studies for barzolvolimab. How that becomes 14 here
Every study that search finds has been read, to see whether and how it gives barzolvolimab. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count
- 10Found by its intervention search · See all 10 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 10 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +4Give it under a name that search misses: a biosimilar’s code or a misspelling
- 14Give barzolvolimab to participants
- 14Test it: the count on this site
Get an email when these change. Save the barzolvolimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
Studies
Open first, then newest update. How each study uses barzolvolimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 14
- Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaEnrolling by invitationPhase 3Celldex TherapeuticsNCT07256392Long-term extension in chronic spontaneous urticariaWritten as barzolvolimabReport a problem
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)RecruitingPhase 3Celldex TherapeuticsNCT07266402In cold urticaria and symptomatic dermographismWritten as BarzolvolimabReport a problem
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaActive, not recruitingPhase 3Celldex TherapeuticsNCT06445023In chronic spontaneous urticaria (EMBARQ-CSU1)Written as barzolvolimabReport a problem
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Active, not recruitingPhase 3Celldex TherapeuticsNCT06455202In chronic spontaneous urticaria (EMBARQ-CSU2)Written as barzolvolimabReport a problem
- A Study of Barzolvolimab in Patients With Atopic DermatitisActive, not recruitingPhase 2Celldex TherapeuticsNCT06727552In atopic dermatitisWritten as BarzolvolimabReport a problem
- A Study of Barzolvolimab in Patients With Prurigo NodularisActive, not recruitingPhase 2Celldex TherapeuticsNCT06366750In prurigo nodularis, phase 2Written as barzolvolimabReport a problem
- A Study of CDX-0159 in Patients With Eosinophilic EsophagitisCompletedPhase 2Celldex TherapeuticsNCT05774184In eosinophilic esophagitisWritten as barzolvolimabReport a problem
- A Study of CDX-0159 in Patients With Chronic Inducible UrticariaCompletedPhase 2Celldex TherapeuticsNCT05405660In chronic inducible urticaria, phase 2Written as barzolvolimabReport a problem
- A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedPhase 2Celldex TherapeuticsNCT05368285In chronic spontaneous urticaria, phase 2Written as barzolvolimabReport a problem
- A Study of CDX-0159 in Patients With Prurigo NodularisCompletedPhase 1Celldex TherapeuticsNCT04944862In prurigo nodularisWritten as CDX-0159Report a problem
- A Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedPhase 1Celldex TherapeuticsNCT04538794In chronic spontaneous urticariaWritten as CDX-0159Report a problem
- A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic UrticariaCompletedPhase 1Celldex TherapeuticsNCT04548869Single dose in chronic inducible urticariaWritten as CDX-0159Report a problem
- A Phase 1 Study of Subcutaneous CDX-0159 in Healthy SubjectsCompletedPhase 1Celldex TherapeuticsNCT05031624Subcutaneous dosing in healthy subjectsWritten as CDX-0159Report a problem
- A Phase 1 Study of CDX-0159CompletedPhase 1Celldex TherapeuticsNCT04146129First in human, single dosesWritten as CDX-0159Report a problem
Tested on its own · 14 — no other medicine in its arm
- Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaEnrolling by invitationPhase 3Celldex TherapeuticsNCT07256392Long-term extension in chronic spontaneous urticariaWritten as barzolvolimabReport a problem
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)RecruitingPhase 3Celldex TherapeuticsNCT07266402In cold urticaria and symptomatic dermographismWritten as BarzolvolimabReport a problem
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaActive, not recruitingPhase 3Celldex TherapeuticsNCT06445023In chronic spontaneous urticaria (EMBARQ-CSU1)Written as barzolvolimabReport a problem
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Active, not recruitingPhase 3Celldex TherapeuticsNCT06455202In chronic spontaneous urticaria (EMBARQ-CSU2)Written as barzolvolimabReport a problem
- A Study of Barzolvolimab in Patients With Atopic DermatitisActive, not recruitingPhase 2Celldex TherapeuticsNCT06727552In atopic dermatitisWritten as BarzolvolimabReport a problem
- A Study of Barzolvolimab in Patients With Prurigo NodularisActive, not recruitingPhase 2Celldex TherapeuticsNCT06366750In prurigo nodularis, phase 2Written as barzolvolimabReport a problem
- A Study of CDX-0159 in Patients With Eosinophilic EsophagitisCompletedPhase 2Celldex TherapeuticsNCT05774184In eosinophilic esophagitisWritten as barzolvolimabReport a problem
- A Study of CDX-0159 in Patients With Chronic Inducible UrticariaCompletedPhase 2Celldex TherapeuticsNCT05405660In chronic inducible urticaria, phase 2Written as barzolvolimabReport a problem
- A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedPhase 2Celldex TherapeuticsNCT05368285In chronic spontaneous urticaria, phase 2Written as barzolvolimabReport a problem
- A Study of CDX-0159 in Patients With Prurigo NodularisCompletedPhase 1Celldex TherapeuticsNCT04944862In prurigo nodularisWritten as CDX-0159Report a problem
- A Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedPhase 1Celldex TherapeuticsNCT04538794In chronic spontaneous urticariaWritten as CDX-0159Report a problem
- A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic UrticariaCompletedPhase 1Celldex TherapeuticsNCT04548869Single dose in chronic inducible urticariaWritten as CDX-0159Report a problem
- A Phase 1 Study of Subcutaneous CDX-0159 in Healthy SubjectsCompletedPhase 1Celldex TherapeuticsNCT05031624Subcutaneous dosing in healthy subjectsWritten as CDX-0159Report a problem
- A Phase 1 Study of CDX-0159CompletedPhase 1Celldex TherapeuticsNCT04146129First in human, single dosesWritten as CDX-0159Report a problem
Codes
What other systems call barzolvolimab · ClinicalTrials.gg INT014845
- UNII (FDA) 4B77GX0NA3BARZOLVOLIMABOne source FDA
- NCI Thesaurus C184860BarzolvolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4B77GX0NA3 | BARZOLVOLIMAB | One source FDA |
| NCI Thesaurus | C184860 | Barzolvolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.